Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses-Reference-Cited by-同舟云学术

Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses

Published:2019-03-13 Issue:1 Volume:14 Page:
ISSN:1748-717X
Container-title:Radiation Oncology
language:en
Short-container-title:Radiat Oncol

Author:

Ni Jianjiao,Li Guodong,Yang Xi,Chu Li,Wang Jialei,Li Yida,Zou Liqing,Li Yuan,Xie Congying,Zhu Zhengfei

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13014-019-1240-1.pdf

Reference34 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68(6):394–424.

2. Takeda M, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann Oncol. 2012;23:2931–6.

3. Hong S, Fang W, Hu Z, et al. A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. Sci Rep. 2014;4:7268.

4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.

5. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study;Oncology Letters;2024-03-22

2. Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT;Journal of Cancer Research and Clinical Oncology;2024-02-19

3. Efficacy and safety analysis of stereotactic body radiotherapy for brain multi-metastases in non-small cell lung cancer patients;Technology and Health Care;2024-01-05

4. International consensus on radiotherapy in metastatic non-small cell lung cancer;Translational Lung Cancer Research;2022-09

5. Optimal Initial Time Point of Local Radiotherapy for Unresectable Lung Adenocarcinoma: A Retrospective Analysis on Overall Arrangement of Local Radiotherapy in Advanced Lung Adenocarcinoma;Frontiers in Oncology;2022-02-10